2016 American Transplant Congress
Outcomes in Obese Renal Transplant Recipients Using High versus Low-Dose Thymoglobulin.
Background: Dosing of rabbit anti-thymocyte globulin (rATG) induction in renal transplant recipients is highly variable by transplant center. Optimizing rATG dose becomes extremely important for…2016 American Transplant Congress
Outcomes of Depleting Antibody Induction in Kidney Transplantation: A Paired Kidney Analysis.
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA.
Induction therapy can improve graft survival following kidney transplantation. Organ quality, a major determinant of graft outcomes may act as a confounder in comparative studies…2015 American Transplant Congress
Propensity Score-Weighted Analysis of Induction Therapies in Live Donor Kidney Transplantation in Modern Immunosuppression Era
1Medicine, UTSW, Dallas, TX; 2Clinical Sciences, UTSW, Dallas, TX; 3Surgery, UTSW, Dallas, TX.
Background: Induction therapy with interleukin-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA…2015 American Transplant Congress
A Comparison of Alemtuzumab and Antithymocyte Globulin Induction in High-Risk, Non-Sensitized African American Renal Transplant Recipients
Background:Greater than 90% of all kidney transplants(KTx) today receive an induction agent. The choice of a depleting or non-depleting agent is center specific. Alemtuzumab (Alem),…2015 American Transplant Congress
Inadequate Overall Immunosuppression Is a Risk for Late Acute Rejection Despite Alemtuzumab Induction in Simultaneous Pancreas Kidney Transplant Recipients
Introduction: Simultaneous pancreas-kidney transplantation (SPK) has become the treatment of choice for patients with end-stage renal disease due to Type 1 Diabetes Mellitus. SPK is…2015 American Transplant Congress
Alemtuzumab Induction Has Been Safe in the United Kingdom and Achieves Long-Term Steroid Avoidance in More Than 80% of Low Risk Renal Transplant Recipients
Introduction: The use of alemtuzumab as an induction agent for renal transplantation is increasing in the UK. There is some evidence to suggest that this…2015 American Transplant Congress
Infections After Alemtuzumab Induction: A Non Issue?
Transplant Institute, Tulane University, New Orleans, LA.
Background: Alemtuzumab is a powerful induction agent that depletes multiple lymphocyte cell lines resulting in leukopenia and/or neutropenia with concerns over infectious complications. This study…2015 American Transplant Congress
Reduced Intensity Immunosuppression Protocol Lowers Drug Costs and May Decrease Incidences of BK Viremia and Readmissions After Kidney and Kidney/Pancreas Transplant
Purpose: To evaluate the effects of a reduced intensity immunosuppression protocol on drug costs and rates of BK viremia and readmissions.Methods: In response to high…2015 American Transplant Congress
Effectiveness of Protocol-Driven Induction Therapy in Adult Kidney Transplant Recipients
Background: Induction therapy significantly improves graft outcomes in kidney transplantation, but the optimal agent based on patient characteristics and immunologic risk is unknown. While many…2015 American Transplant Congress
Early Use of Anti-Lymphocyte Antibody in Kidney Transplant Recipients With Delayed Graft Function Can Produce Desirable Post-Transplant Results
Department of Transplantation Surgery, Yonsei University Health System, Seoul, Republic of Korea.
Proper management of delayed graft function (DGF) is essential for successful post-transplant result in deceased donor kidney transplantation. We compared the effect of anti-lymphocyte antibody…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 31
- Next Page »